Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed a Form 8-K on January 8, 2024, reporting preliminary financial results for the fourth quarter and full year ended December 31, 2023. The company operates in the biopharmaceutical sector, focusing on RNAi therapeutics.
Key Financial Metrics
- Q4 2023 Net Product Revenues: Approximately $346 million.
- Full Year 2023 Net Product Revenues: Approximately $1,241 million.
- Product Portfolio: Revenues derived from ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran).
- Liquidity: As of December 31, 2023, the company held approximately $2.4 billion in cash, cash equivalents, and marketable securities.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or total debt.
Material Changes
The filing presents preliminary absolute revenue figures for the current period but does not explicitly state percentage changes or comparative figures versus the prior comparable period (Q4 2022 or Full Year 2022) within the provided text.
Guidance, Outlook, and Risks
The reported financial results are unaudited, preliminary, and subject to adjustment. The company indicated that complete financial results will be announced in February 2024. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for these specific preliminary figures. No specific forward-looking guidance or risk factors were detailed in this excerpt beyond the standard disclaimer regarding preliminary data.
Investor Verification Checklist
- Verify the final audited revenue figures when the complete financial results are released in February 2024.
- Confirm the breakdown of revenue by individual product (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO) in the upcoming full report.
- Review the full year 2023 net income, operating expenses, and cash flow statement to assess profitability and burn rate.
- Check for any updates on debt obligations or capital expenditure plans not included in this preliminary summary.